NEW YORK (GenomeWeb News) — Pronota has won a €1.9 million ($2.7 million) grant from the Flanders government to further develop its diagnostic and pharmacodiagnostic protein biomarker-discovery and -validation platform, the Belgian company said today.
Pronota said the grant, which is being awarded through IWT-Flanders, will be used to expand the development of Pronota's first-generation biomarker-discovery platform by building on its capability to identify low-abundant serum protein biomarkers.
The company said it will use its low-abundant serum protein biomarkers to develop the new discovery platform, which it will couple with a “novel validation platform.”
Taken together, the integrated platforms will allow researchers to “simultaneously assess the levels of a significant number of candidate biomarkers in large patient populations without the upfront requirement to generate antibodies and develop immunoassays.”
Funds left over from the primary programs will be used to support “one of Pronota’s internal biomarker-discovery programs,” the company said.